{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:46:37Z","timestamp":1790754397692,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec><jats:label\/><jats:p><jats:bold>Background:<\/jats:bold> Early changes in PSA have been evaluated in association to treatment outcome. The aim of this study was to assess PSA surge phenomenon in castration\u2010resistant prostate cancer (CRPC) patients treated with abiraterone and to correlate those variations with long\u2010term treatment outcome.<\/jats:p><jats:p><jats:bold>Patients and Methods:<\/jats:bold> We retrospectively evaluated 330 CRPC patients in 11 Italian hospitals, monitoring PSA levels at baseline and every 4 weeks. Other clinical, biochemical and molecular parameters were determined at baseline. We considered PSA surge as PSA increase within the first 8 weeks from starting abiraterone more than 1% from baseline followed by a PSA decline. The log\u2010rank test was applied to compare survival between groups of patients according to PSA surge. The impact of PSA surge on survival was evaluated by Cox regression analyses.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 330 patients with CRPC, median age 74 years (range, 45\u201390), received abiraterone (281 chemotherapy\u2010treated and 49 chemotherapy\u2010na\u00efve). PSA surge was observed in 20 (7%) post\u2010chemotherapy and 2 (4%) chemotherapy\u2010na\u00efve patients. For overall patients presenting PSA surge, timing of PSA peak from baseline was 5\u2009\u00b1\u20091.8 weeks and PSA rise from baseline was 21\u2009\u00b1\u200918.4%. The overall median follow\u2010up was 23 months (range 1\u201362). No significant differences in progression\u2010free survival and overall survival were observed between patients with and without PSA surge (<jats:italic>P<\/jats:italic>\u2009=\u20090.16 and =0.86, respectively). In addition, uni\u2010 and multivariate analyses showed no baseline factors related to PSA surge.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> PSA surge occurs in both chemotherapy\u2010treated and chemotherapy\u2010na\u00efve patients treated with abiraterone resulting, however, in no long\u2010term impact on outcome. Physicians and patients should be aware of PSA surge challenge to prevent a premature discontinuation of potentially effective therapy with abiraterone. Further larger and prospective studies are warranted to investigate this not infrequent phenomenon.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.23357","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T03:36:51Z","timestamp":1492745811000},"page":"1012-1019","source":"Crossref","is-referenced-by-count":8,"title":["Long\u2010term clinical impact of PSA surge in castration\u2010resistant prostate cancer patients treated with abiraterone"],"prefix":"10.1002","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-714X","authenticated-orcid":false,"given":"Vincenza","family":"Conteduca","sequence":"first","affiliation":[{"name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Santa Chiara Hospital Trento Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[{"name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Aieta","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Istituto di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata Rionero in Vulture Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Scarpi","sequence":"additional","affiliation":[{"name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit Infermi Hospital Rimini Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Maines","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Santa Chiara Hospital Trento Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schepisi","sequence":"additional","affiliation":[{"name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Salvi","sequence":"additional","affiliation":[{"name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[{"name":"Division of Oncology S.Orsola\u2010Malpighi Hospital Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Carrozza","sequence":"additional","affiliation":[{"name":"Oncology Unit City Hospital Faenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Veccia","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Santa Chiara Hospital Trento Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo E.","family":"Chiuri","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit Vito Fazzi Hospital Lecce Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Campadelli","sequence":"additional","affiliation":[{"name":"Oncology Unit Umberto I Hospital Lugo di Romagna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Department of Uro\u2010Gynaecological Oncology Istituto Nazionale Tumori \u201cFondazione G. Pascale\u201d \u2212 Istituto di Ricovero e Cura a Carattere Scientifico Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710083171501"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009448"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.06.010"},{"key":"e_1_2_9_9_1","article-title":"Prostate\u2010specific antigen flare phenomenon induced by abiraterone acetate in chemotherapy\u2010naive patients with metastatic castration\u2010resistant prostate cancer","author":"Ueda Y","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21024"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9511"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.128"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9341"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx155"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0071"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22890"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158952"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00376"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908173210702"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908173210701"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07873.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-007-9221-y"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.03.015"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13483"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000070658"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14406"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091520"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00123"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.070"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.028"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000231468.69535.97"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9485"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2558"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.014"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt136"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt138"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.028"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23357","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.23357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T17:24:44Z","timestamp":1694971484000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.23357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1002\/pros.23357"],"URL":"https:\/\/doi.org\/10.1002\/pros.23357","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,20]]}}}